Zydus Cadila has received tentative approval from the US FDA to market empagliflozin tablets in the strengths of 10 mg and 25 mg.
The medication is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. It is also used to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad. The group has 286 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.